Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Distribution of subsequent treatments after treatment with immunotherapies

From: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

 

Distribution

Source

Chemotherapy

Pemetrexed

60%

Expert opinion

Gemcitabine

10%

Carboplatin

45%

Cisplatin

20%

Paclitaxel

5%

Docetaxel

10%

Vinorelbine

30%

Targeted therapy

Bevacizumab

5%

Expert opinion

Nintedanib

5%

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us